PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

Challenges of Small Molecule Production

Over the last 10 years (2008–2017), the United States FDA approved a total of 320 new drugs. Of these, 249 were new chemical entities (NCE) or small molecules, about 78% of the market share. In the same period, the average number of biologics doubled to seven biologic license applications (BLA) per year. Biologics are indeed on the rise. However, the average number of NCEs has not decreased either. The average number of NCEs approved by the FDA has increased slightly from 22 compounds a year in the late 90s to 24 in this decade. This article by Lester C. Taylor and Tilak
Chandrasekaran at Agilent Technologies evaluates the opportunities for small molecules, and how they can stay relevant in this ever-changing landscape. The challenges in production are discussed, including process scale-up, optimisation, analytical methods, supply chain, technology and knowledge transfer issues, and keeping up with regulations.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/Challenges-of-small-molecule-production.pdf” width=”100%” height=”900px” style=”border:0;”]

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025